Get the Stockscreener App
44.93
1.81%
-0.83
After Hours:
44.25
-0.68
-1.51%
Crinetics Pharmaceuticals Inc stock is traded at $44.93, with a volume of 1.37M.
It is down -1.81% in the last 24 hours and up +28.37% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$45.76
Open:
$46.05
24h Volume:
1.37M
Relative Volume:
1.00
Market Cap:
$4.23B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-12.05
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
+9.96%
1M Performance:
+28.37%
6M Performance:
+67.34%
1Y Performance:
-13.23%
1-Day Range:
$44.20
$46.05
1-Week Range:
$40.77
$46.05
52-Week Range:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
44.93 | 4.31B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
What candlestick patterns are forming on Crinetics Pharmaceuticals Inc.July 2025 Catalysts & Weekly Momentum Picks - newser.com
What recovery options are there for Crinetics Pharmaceuticals Inc.Earnings Recap Summary & Proven Capital Preservation Methods - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
How to use a screener to detect Crinetics Pharmaceuticals Inc. breakouts2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Is it too late to sell Crinetics Pharmaceuticals Inc.Market Trend Summary & Verified Swing Trading Watchlists - newser.com
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Will a bounce in Crinetics Pharmaceuticals Inc. offer an exit2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Crinetics stock holds Overweight rating at Piper Sandler after acromegaly drug approval - Investing.com Canada
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com Nigeria
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) - Yahoo
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month - Sahm
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Using portfolio simulators with Crinetics Pharmaceuticals Inc. includedWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Crinetics Pharmaceuticals Inc.Earnings Recap Report & Capital Efficient Trade Techniques - newser.com
Does Crinetics Pharmaceuticals Inc. fit your quant trading model2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Comparing Crinetics Pharmaceuticals Inc. in custom built stock radarsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized - Sahm
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock - MarketBeat
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price - Markets Mojo
How analysts revise price targets for Crinetics Pharmaceuticals Inc. (6Z4) stockJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Crinetics Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Matthew Fust Sells 16,000 Shares - MarketBeat
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outper - GuruFocus
Crinetics Pharmaceuticals (CRNX) Price Target Increased by 11.63% to 81.09 - Nasdaq
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - MSN
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outperform Rating | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Opens with 14.43% Gain, Surpassing S&P 500's 0.59% Rise - Markets Mojo
Crinetics Pharmaceuticals Inc 6Z4 Stock Analysis and ForecastQuarterly Earnings Review & Small Investment Capital Tips - earlytimes.in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $87.00 at Oppenheimer - MarketBeat
Crinetics Pharmaceuticals Rings the Opening Bell - Nasdaq
What drives Crinetics Pharmaceuticals Inc stock priceFederal Reserve Announcements & Rapid Wealth Building Tips - earlytimes.in
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating - MSN
What drives Crinetics Pharmaceuticals Inc 6Z4 stock priceCapital Gains Strategies & Lower Drawdowns With Smart Position Sizing - earlytimes.in
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug - Yahoo Finance
Morgan Stanley Raises Price Target for CRNX to $77 | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.1%Should You Sell? - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 01 '25 |
Sale |
41.81 |
5,000 |
209,050 |
66,270 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):